drugset / Trial / NCT01161355

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

NCT01161355

Phase 1 Completed 6 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The primary objective of this study is to assess the absolute bioavailability and to evaluate pharmacokinetic parameters of a single oral dose and a radiolabelled intravenous microdose of \[14C\]AZD9668 in healthy male subjects.

Timeline

Start
2010-06
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvelestat Small molecule Oral

Indications

No indication recorded.